Literature DB >> 2338089

In vitro synergism of rifampin-cephalosporin combinations against Haemophilus influenzae type b.

R C Gordon1, R Wofford-McQueen, K Shu.   

Abstract

The in vitro susceptibility of Haemophilus influenzae type b to rifampin, cefotaxime, ceftazidime, ceftriaxone and cefuroxime was examined at inocula of 10(5) and 10(7) CFU/ml. Time-kill curves were then obtained using antibiotic concentrations at one-half the MIC for each drug at the two inocula with combinations of rifampin plus each of the cephalosporins. There was a pronounced inoculum effect with all of the cephalosporins except for cefuroxime, but the MIC values were also higher for the latter drug. The rare failure of some cephalosporins to promptly sterilize the cerebrospinal fluid in meningitis should encourage investigation of the relationship between the inoculum effect, minimum bactericidal concentration and cerebrospinal fluid antibiotic levels in these clinical situations. A marked synergistic effect was noted for most of the isolates, and therefore, cephalosporin-rifampin combinations might show clinical utility.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2338089     DOI: 10.1007/bf01963838

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

1.  Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis.

Authors:  W E Feldman
Journal:  J Pediatr       Date:  1976-04       Impact factor: 4.406

Review 2.  Cefuroxime treatment failure and Haemophilus influenzae meningitis: case report and review of literature.

Authors:  M Arditi; B C Herold; R Yogev
Journal:  Pediatrics       Date:  1989-07       Impact factor: 7.124

3.  Addition of rifampicin in persistent Haemophilus influenzae type B meningitis.

Authors:  M A Lewis; B L Priestley
Journal:  Br Med J (Clin Res Ed)       Date:  1986-02-15

4.  Addition of rifampicin in persistent Haemophilus influenzae type B meningitis.

Authors:  C I Haines; M Patfield
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-29

5.  Delayed sterilization of Haemophilus influenzae type b meningitis with twice-daily ceftriaxone.

Authors:  R F Jacobs; M W Wright; R L Deskin; R W Bradsher
Journal:  JAMA       Date:  1988-01-15       Impact factor: 56.272

6.  Minor synergy and antagonism may be clinically important.

Authors:  M C Berenbaum
Journal:  J Antimicrob Chemother       Date:  1987-02       Impact factor: 5.790

7.  In vitro interactions between rifampin and ampicillin or chloramphenicol against Haemophilus influenzae.

Authors:  T Jadavji; C G Prober; R Cheung
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

8.  Effect of inoculum size on Haemophilus influenzae type b susceptibility to new and conventional antibiotics.

Authors:  C Laferriere; M I Marks; D F Welch
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

9.  Correlations between methods for measurement of synergy.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1980-09       Impact factor: 5.226

Review 10.  Rifampin.

Authors:  B Farr; G L Mandell
Journal:  Med Clin North Am       Date:  1982-01       Impact factor: 5.456

  10 in total
  4 in total

1.  Inoculum effect of β-lactam antibiotics.

Authors:  Justin R Lenhard; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

Review 2.  Antibiotic resistance in Haemophilus influenzae: mechanisms, clinical importance and consequences for therapy.

Authors:  R de Groot; G Dzoljic-Danilovic; B van Klingeren; W H Goessens; H J Neyens
Journal:  Eur J Pediatr       Date:  1991-06       Impact factor: 3.183

Review 3.  Use of rifampin in nonstaphylococcal, nonmycobacterial disease.

Authors:  A B Morris; R B Brown; M Sands
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

Review 4.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.